Workflow
United Therapeutics(UTHR)
icon
Search documents
United Therapeutics(UTHR) - 2022 Q2 - Quarterly Report
2022-08-02 16:00
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2022 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (301) 608-9292 (Registrant's Telephone Number, Including Area Code) (Former Name, Former Address and Former Fiscal Year, If Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of exchange ...
United Therapeutics(UTHR) - 2022 Q1 - Earnings Call Transcript
2022-05-04 16:06
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2022 Results Conference Call May 4, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Leigh Peterson - SVP, Product Development Patrick Poisson - EVP, Technical Operations Conference Call Participants Andreas Argyrides - Wedbush Securities Eun Yang – Jefferies Jessica Fye – JPMorgan Joseph Thome - Cowen & Company Operator Good morning, and welcome to the United Therapeutics C ...
United Therapeutics(UTHR) - 2022 Q1 - Quarterly Report
2022-05-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...
United Therapeutics(UTHR) - 2021 Q4 - Earnings Call Transcript
2022-02-27 15:14
United Therapeutics Corporation (NASDAQ:UTHR) Q4 2021 Earnings Conference Call February 24, 2022 9:00 AM ET Company Participants Dewey Steadman - Head of IR Martine Rothblatt - Founder, Chairman and CEO Michael Benkowitz - President and COO Conference Call Participants Joseph Thome - Cowen and Company Eun Yang - Jefferies LLC Jessica Fye - JPMorgan Andreas Argyrides - Wedbush Securities Inc. Operator Good morning, and welcome to the United Therapeutics Corporation Fourth Quarter and Full Year 2021 Earnings ...
United Therapeutics(UTHR) - 2021 Q4 - Annual Report
2022-02-23 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 Registrant's Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Title of each cl ...
United Therapeutics(UTHR) - 2021 Q3 - Earnings Call Transcript
2021-11-03 18:49
United Therapeutics Corporation (NASDAQ:UTHR) Q3 2021 Earnings Conference Call November 3, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Joseph Thome - Cowen and Company Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer Eun Yang - Jefferies Operator Good morning and welcome to the United Therapeutics Corporati ...
United Therapeutics(UTHR) - 2021 Q3 - Quarterly Report
2021-11-02 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-1984749 (State or Other Jurisdiction of (I.R.S. Employ ...
United Therapeutics(UTHR) - 2021 Q2 - Earnings Call Transcript
2021-08-04 17:12
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2021 Earnings Conference Call August 4, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Senior Vice President, Product Development Conference Call Participants Jessica Fye - JPMorgan Hartaj Singh - Oppenheimer & Company Joseph Thome - Cowen & ...
United Therapeutics(UTHR) - 2021 Q2 - Quarterly Report
2021-08-03 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission file number 0-26301 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.01 ...
United Therapeutics(UTHR) - 2021 Q1 - Earnings Call Transcript
2021-05-05 17:55
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2021 Earnings Conference Call May 5, 2021 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson and CEO Michael Benkowitz - President and COO Leigh Peterson - SVP, Product Development James Edgemond - CFO and Treasurer Conference Call Participants Eun Yang - Jefferies Liana Moussatos - Wedbush Securities Hartaj Singh - Oppenheimer & Company Joe Thome - Cowen & Company Operator Good morning, and welcome to the United Therape ...